drugset
drugset / Trial / NCT06904105

A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity

NCT06904105 ↗

Phase 3 Active not recruiting 556 enrolled Shandong Suncadia Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.

Timeline

Start
2025-04-09
Primary completion
2026-05
Completion
2026-05

Outcome

Met primary endpoint

release “HARBOR-1 met its primary endpoint, achievement of superior weight reduction at Week 44 with HRS-7535 compared to placebo.” kailera.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-7535 Small molecule — —

Indications

obesity disorder